SAR vs. SNG, IMM, BVX, NSCI, OBI, OPTI, DEST, ROQ, OBD, and GENF
Should you be buying Sareum stock or one of its competitors? The main competitors of Sareum include Synairgen (SNG), ImmuPharma (IMM), BiVictriX Therapeutics (BVX), NetScientific (NSCI), Ondine Biomedical (OBI), OptiBiotix Health (OPTI), Destiny Pharma (DEST), Roquefort Therapeutics (ROQ), Oxford BioDynamics (OBD), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.
Sareum (LON:SAR) and Synairgen (LON:SNG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk.
Synairgen's return on equity of -48.86% beat Sareum's return on equity.
Sareum presently has a consensus price target of GBX 304, indicating a potential upside of 835.38%. Given Sareum's higher probable upside, equities research analysts clearly believe Sareum is more favorable than Synairgen.
In the previous week, Sareum and Sareum both had 1 articles in the media. Sareum's average media sentiment score of 0.67 beat Synairgen's score of 0.00 indicating that Sareum is being referred to more favorably in the media.
28.6% of Synairgen shares are held by institutional investors. 6.1% of Sareum shares are held by insiders. Comparatively, 3.1% of Synairgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Synairgen received 71 more outperform votes than Sareum when rated by MarketBeat users. However, 66.13% of users gave Sareum an outperform vote while only 56.46% of users gave Synairgen an outperform vote.
Sareum has a beta of -0.69, meaning that its share price is 169% less volatile than the S&P 500. Comparatively, Synairgen has a beta of -2.23, meaning that its share price is 323% less volatile than the S&P 500.
Sareum has higher earnings, but lower revenue than Synairgen. Sareum is trading at a lower price-to-earnings ratio than Synairgen, indicating that it is currently the more affordable of the two stocks.
Summary
Sareum beats Synairgen on 8 of the 14 factors compared between the two stocks.
Get Sareum News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
